• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TNFA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    RAUCH GARY M

    (Last) (First) (Middle)
    1185 AVENUE OF THE AMERICAS, SUITE 249

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    TNF Pharmaceuticals, Inc. [ TNFA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Vice President, Finance
    3. Date of Earliest Transaction (Month/Day/Year)
    04/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) $0.1832 04/17/2025 A 75,000 04/18/2025 04/16/2035(1) Common Stock 75,000 $0 75,000 D
    Explanation of Responses:
    1. The stock options are subject to expiration if the employment of the Reporting Person is terminated.
    /s/ Gary Rauch 04/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TNFA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNFA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TNFA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

    Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

    9/25/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

    New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

    9/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

    9/17/25 9:24:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by President, CMO Glass Mitchell

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:12 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Interim CFO Rhodes Ian

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:14 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    SEC Filings

    View All

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    9/26/25 5:10:36 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/10/25 5:00:34 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:47 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Financials

    Live finance-specific insights

    View All

    TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

    Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

    3/5/25 9:00:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care